(Press-News.org) The experimental drug nintedanib, combined with standard chemotherapy with paclitaxel, causes a total remission of tumours in 50% of patients suffering from early HER-2- negative breast cancer, the most common type of breast cancer. These are the conclusions of the Phase I Clinical Trial, sponsored by the Spanish National Cancer Research Centre (CNIO) and carried out by CNIO ́s Breast Cancer Clinical Research Unit. The study has been published today in British Journal of Cancer, which belongs to Nature Publishing Group.
According to Miguel Ángel Quintela, head of the Unit: "The drug combination of paclitaxel and nintedanib has turned out to be a complete success, given that it is proved to be safe and that the pathologic complete response [rate of complete recovery] was 50%, which doubles the response compared to patients treated with standard therapy with paclitaxel." The trial has also included 10 HER-2-negative breast cancer patients, all of them in early stages of the disease.
In light of the results, the CNIO Breast Cancer Clinical Research Unit has already launched a large-scale Phase II Clinical Trial to validate the results in a large group of patients. These results, including biomarker studies that will facilitate advances in personalised medicine, will be released by early 2015.
In parallel, the Unit has just completed a second Phase I Clinical Trial with a drug of the same family named dovitinib. The study has been tested in metastatic patients with different primary tumours such as breast, colon and lung cancer. The results, still in a preliminary stage, show that patients with a specific variant in the RET gene -a proto-oncogene or cancer driver gene; variant G2071A- could be more sensitive to this drug. This work has been published by Molecular Oncology.
As Quintela says, if these data are confirmed, this genetic variant -present in 15% of Caucasian people- could be used as a reliable biomarker in personalised medicine to select the best suited candidates to receive this drug.
'SUFFOCATE' THE TUMOUR TO FIGHT IT
Recent theories suggest that a possible solution to cancer might be to 'suffocate the tumour' by blocking the formation of new blood vessels that surround it.
The mechanism of action of the experimental drugs nintedanib (Boehringer Ingelheim) and dovitinib (Novartis) precisely consists on blocking the formation of new blood vessels, so-called angiogenesis, which can lead to retardation in tumour growth rates and limit its viability.
"Nintedanib [a drug that there is more experimental data on] is an improved antiangiogenic drug compared to previous angiogenesis inhibitors, given that it prevents angiogenesis in a more efficient way and with lower toxicity than its predecessors", explains Quintela.
Nintedanib, in addition to blocking vascular endothelial growth factor receptors (VEGFR) and platelet derived growth factor receptors (PDGFR), also acts on fibroblast growth factor receptors (FGFR), which makes it different to classical angiogenesis inhibitors.
FGFRs work in an aberrant manner in 10-15% of HER-2 negative breast cancers, which could explain a greater the compound's greater anti- tumour activity compared to other compounds.
FIRST CLINICAL TRIALS SPONSORED BY CNIO
After becoming one of the world's leading cancer research centres, one of CNIO ́s aims is to undertake developing a comprehensive project for excellence in oncology research, where the pathology can be looked at from different basic and translational viewpoints to facilitate the conversion of scientific knowledge into advances that benefit the care of patients.
An effective way to achieve that is by conducting clinical trials for cancer patients launched by the Clinical Research Programme, directed by oncologist Manuel Hidalgo.
"The clinical trials we are presenting are the first organised by CNIO, to whom several pharmaceutical companies have entrusted complete development of the previously mentioned experimental drugs", says Quintela. As the researcher explains, this "wouldn't have been possible without the fluid collaboration of hospitals from the Spanish National Health System, and the Spanish Breast Cancer Research Group".
Hidalgo says: "doing this type of study is critical to be able to test hypotheses formulated in the laboratory on patients without commercial pressures", adding that: "these studies show that it is possible to create a network of research centres and hospitals to carry out clinical trials with a strong scientific component".
INFORMATION: END
CNIO successfully completes its fisrt clinical trial on HER-2-negative breast cancer with nintedanib
Nintedanib in combination with paclitaxel for the treatment of early HER-2-negative breast cancer causes a total remission of tumors in 50 percent of the patients
2014-09-10
ELSE PRESS RELEASES FROM THIS DATE:
Monitoring the response of bone metastases to treatment using MRI and PET
2014-09-10
Imaging technologies are very useful in evaluating a patient's response to cancer treatment, and this can be done quite effectively for most tumors using RECIST, Response Evaluation Criteria in Solid Tumors. However, RECIST works well for tumors located in soft tissue, but not so well for cancers that spread to the bone, such as is the case for prostate and breast cancers. More effort, therefore, is needed to improve our understanding of how to monitor the response of bone metastases to treatment using magnetic resonance imaging (MRI) and positron emission tomography (PET), ...
'Electronic skin' could improve early breast cancer detection
2014-09-10
For detecting cancer, manual breast exams seem low-tech compared to other methods such as MRI. But scientists are now developing an "electronic skin" that "feels" and images small lumps that fingers can miss. Knowing the size and shape of a lump could allow for earlier identification of breast cancer, which could save lives. They describe their device, which they've tested on a breast model made of silicone, in the journal ACS Applied Materials & Interfaces.
Ravi F. Saraf and Chieu Van Nguyen point out that early diagnosis of breast cancer, the most common type of cancer ...
A Mexican plant could lend the perfume industry more green credibility
2014-09-10
The mere whiff of a dreamy perfume can help conjure new feelings or stir a longing for the past. But the creation of these alluring scents, from the high-end to the commonplace, can also incur an environmental toll. That could change as scientists, reporting in the journal ACS Sustainable Chemistry & Engineering, examine a more sustainable way to produce a key perfume ingredient and supply it to fragrance makers around the world.
José M. Ponce-Ortega and colleagues explain that out of the three main ingredients in perfumes, the fixatives, which allow a scent to linger ...
Unnecessary antibiotic use responsible for $163M in potentially avoidable hospital costs
2014-09-10
Arlington, Va. (September 10, 2014) – The Centers for Disease Control and Prevention (CDC) and Premier, Inc. have released new research on the widespread use of unnecessary and duplicative antibiotics in U.S. hospitals, which could have led to an estimated $163 million in excess costs. The inappropriate use of antibiotics can increase risk to patient safety, reduce the efficacy of these drugs and drive up avoidable healthcare costs. The study is published in the October issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology ...
Ancient swamp creature had lips like Mick Jagger
2014-09-10
DURHAM, N.C. -- Sir Mick Jagger has a new animal named after him. Scientists have named an extinct swamp-dwelling creature that lived 19 million years ago in Africa after the Rolling Stones frontman, in honor of a trait they both share -- their supersized lips.
"We gave it the scientific name Jaggermeryx naida, which translates to 'Jagger's water nymph,'" said study co-author Ellen Miller of Wake Forest University. The animal's fossilized jaw bones suggest it was roughly the size of a small deer and akin to a cross between a slender hippo and a long-legged pig.
Researchers ...
Healthcare workers wash hands more often when in presence of peers
2014-09-10
CHICAGO (September 10, 2014) – Nationally, hand hygiene adherence by healthcare workers remains staggeringly low despite its critical importance in infection control. A study in the October issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America (SHEA), found that healthcare workers' adherence to hand hygiene is better when other workers are nearby.
"Social network effects, or peer effects, have been associated with smoking, obesity, happiness and worker productivity. As we found, this influence extends ...
A novel method for portable detection of potent drugs known as 'bath salts'
2014-09-10
Despite being outlawed in 2012 in the U.S., the synthetic drugs known as "bath salts" — which really aren't meant for your daily bath — are still readily available in some retail shops, on the Internet and on the streets. To help law enforcement, scientists are developing a novel method that could be the basis for the first portable, on-site testing device for identifying the drugs. They report their advance in the ACS journal Analytical Chemistry.
Craig E. Banks, in collaboration with Oliver Sutcliffe, notes that the high-inducing substances in bath salts, which are ...
Scientists express concern over long-term vision for satellite-based research
2014-09-10
The U.S. has more than 30 civilian, Earth-observing satellites circling the planet, providing scientists with a torrent of crucial environmental and climate information. More satellites are on deck to launch in the next few years. But, according to an article in Chemical & Engineering News (C&EN), the weekly news magazine of the American Chemical Society, scientists have registered serious concerns over the lack of a long-term, cohesive vision for the scientific missions.
Jyllian Kemsley, a senior editor at C&EN, reports that satellites are marvels of technology. From ...
Penn engineers advance understanding of graphene's friction properties
2014-09-10
An interdisciplinary team of engineers from the University of Pennsylvania has made a discovery regarding the surface properties of graphene, the Nobel-prize winning material that consists of an atomically thin sheet of carbon atoms.
On the macroscale, adding fluorine atoms to carbon-based materials makes for water-repellant, non-stick surfaces, such as Teflon. However, on the nanoscale, adding fluorine to graphene had been reported to vastly increase the friction experienced when sliding against the material.
Through a combination of physical experiments and atomistic ...
Video game teaches kids how to code
2014-09-10
Computer scientists at the University of California, San Diego have successfully funded on Kickstarter a new and improved version of CodeSpells, a first-person player game they developed that teaches players how to code.
The game's previous iteration, developed by UC San Diego computer science Ph.D. students Sarah Esper and Stephen Foster, has been in use in dozens of schools throughout the world for more than a year. The researchers have been using the game as a platform to learn about the best ways to teach children how to code. They have presented their findings at ...
LAST 30 PRESS RELEASES:
Capturability distinction analysis of continuous and pulsed guidance laws
CHEST expands Bridging Specialties Initiative to include NTM disease and bronchiectasis on World Bronchiectasis Day
Exposure to air pollution may cause heart damage
SwRI, UTSA selected by NASA to test electrolyzer technology aboard parabolic flight
Prebiotics might be a factor in preventing or treating issues caused by low brain GABA
Youngest in class at higher risk of mental health problems
American Heart Association announces new volunteer leaders for 2025-26
Gut microbiota analysis can help catch gestational diabetes
FAU’s Paulina DeVito awarded prestigious NSF Graduate Research Fellowship
Champions for change – Paid time off initiative just made clinical trials participation easier
Fentanyl detection through packaging
Prof. Eran Meshorer elected to EMBO for pioneering work in epigenetics
New 3D glacier visualizations provide insights into a hotter Earth
Creativity across disciplines
Consequences of low Antarctic sea ice
Hear here: How loudness and acoustic cues help us judge where a speaker is facing
A unique method of rare-earth recycling can strengthen the raw material independence of Europe and America
Epilepsy self-management program shows promise to control seizures, improve mood and quality of life
Fat may play an important role in brain metabolism
New study finds no lasting impact of pandemic pet ownership on human well-being
New insights on genetic damage of some chemotherapies could guide future treatments with less harmful side effects
Gut microbes could protect us from toxic ‘forever chemicals’
Novel modelling links sea ice loss to Antarctic ice shelf calving events
Scientists can tell how fast you're aging from a single brain scan
U.S. uterine cancer incidence and mortality rates expected to significantly increase by 2050
Public take the lead in discovery of new exploding star
What are they vaping? Study reveals alarming surge in adolescent vaping of THC, CBD, and synthetic cannabinoids
ECMWF - delivering forecasts over 10 times faster and cutting energy usage by 1000
Brazilian neuroscientist reveals how viral infections transform the brain through microscopic detective work
Turning social fragmentation into action through discovering relatedness
[Press-News.org] CNIO successfully completes its fisrt clinical trial on HER-2-negative breast cancer with nintedanibNintedanib in combination with paclitaxel for the treatment of early HER-2-negative breast cancer causes a total remission of tumors in 50 percent of the patients